- Company
- When will Xocova be approved in Korea?
- by Nho, Byung Chul Nov 30, 2022 05:53am
- With the new oral COVID-19 treatment Xocova starting prescriptions in Japan after obtaining emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW), attention is rising on whether it will be approved in Korea as well. In Korea, the Korea Disease Control and Prevention Agency determines the need and grants E
- Company
- Doveprella, the first new tuberculosis drug in 50 years,
- by Eo, Yun-Ho Nov 30, 2022 05:52am
- Doveprella, a new tuberculosis drug that appeared 50 years, is expected to be listed on the insurance benefit list. According to related industries, Viatris' multidrug-resistant tuberculosis treatment Doveprella recently concluded a drug price negotiation with the NHIS. After passing the HIRA's Drug Benefit Evaluation Committee in September,
- Company
- Oluminant's sales are higher than Xeljanz's
- by Kim, Jin-Gu Nov 30, 2022 05:52am
- Xeljanz lost its market lead by falling sales by 13% due to safety issues. The market for JAK inhibitors, an oral autoimmune disease treatment drug, is fluctuating. While long-time market leader Pfizer Xeljanz faltered, Lilly's Oluminant took the lead. On top of that, Abbvie Rinvoq quickly expanded its sales, signaling fierce competition.
- Company
- Boryung, start patent challenge for liver cancer drug Lenvim
- by Kim, Jin-Gu Nov 30, 2022 05:52am
- Boryung challenged Eisai's patent for Lenvima, a liver cancer treatment. It is interpreted as a strategy to spur the anti-cancer drug business, which has been strongly driving since 2020. According to the pharmaceutical industry on the 29th, Boryung recently filed a passive judgment on the scope of rights and a judgment on invalidity in three
- Company
- Samsung Bioepis occupies 25% of Avastin mkt 1yr since launch
- by Nov 30, 2022 05:52am
- Samsung Bioepis’s Avastin (bevacizumab) biosimilar ‘Onbevzi’ is enjoying its market preoccupation effect. In only one year since its release, the share of its similar reached nearly 25% in the market. With Alvogen and Celltrion’s biosimilars succeeding to be released with reimbursement from the next month, the competition between biosimilars
- Company
- Rolontis and Leclaza make their place in Korea
- by Chon, Seung-Hyun Nov 29, 2022 05:54am
- Leclaza and Rolontis, the homegrown drugs that have gained attention as promising new global drugs, have made a smooth start in the domestic market. Yuhan Corp’s Leclaza’s annual sales exceeded KRW 10 billion in the second year of release, and Hanmi Pharmaceutical’s Rolontis has also started making sales in earnest in the Korean market.
- Company
- Keytruda has booked high sales in the domestic market
- by Chon, Seung-Hyun Nov 29, 2022 05:53am
- Keytruda, an immuno-cancer drug, has reserved a leading position in the domestic pharmaceutical market for 3 consecutive years. New drug products recently released by multinational pharmaceutical companies such as Gardasil 9 and Dupixent continued to be high. According to IQVIA, a pharmaceutical research firm, MSD Keytruda posted 161.6 billion w
- Company
- First targeted PIK3CA Piqray reapplies for reimb
- by Eo, Yun-Ho Nov 28, 2022 05:51am
- An anticancer drug that targets the PIK3CA gene will once again attempt reimbursement listing in Korea. According to industry sources, Novartis Korea submitted a reimbursement application for the reimbursement of its breast cancer treatment Piqray (alpelisib) recently. The drug was unable to pass deliberations by the Health Insurance Revi
- Company
- K-similars compete for Canada's ₩31 tril market
- by Nov 25, 2022 06:05am
- Biosimilars manufactured by domestic bio companies are targeting Canada, the world's 10th largest pharmaceutical market With an increasing number of provinces in Canada actively implementing policies to mandate the use of biosimilars, usage of biosimilars in the country, which had been in the 10% range, is expected to increase significantly.
- Company
- Janssen Korea to reduce workforce...conducts VSP
- by Eo, Yun-Ho Nov 25, 2022 06:05am
- Janssen Korea plans to restructure its labor force. According to industry sources, Janssen finalized its decision to conduct a Volunteer Separate Program (VSP) in its town hall meeting. The company will receive applications for VSP until the 30th of this month and does not have a fixed number of reductions planned. The specific term
